Browse our 650+ Publications​

Latest Publications

Immunosequencing of the T-cell receptor repertoire reveals signatures specific for diagnosis and characterization of early Lyme disease

Greissl J, et al.
August 2021
Authors and Affiliates
Julia Greissl *,a, Mitch Pesesky *,b, Sudeb C. Dalai b,c, Alison W. Rebman d, Mark J. Soloski d, Elizabeth J. Horn e, Jennifer N. Dines b, Rachel M. Gittelman b, Thomas M. Snyder b, Ryan O. Emerson b, Edward Meeds a, Thomas Manley b, Ian M. Kaplan b, Lance Baldo b, Jonathan M. Carlson a,†, Harlan S. Robins †,b, John N. Aucott †,d; *Julia Greissl and Mitch Pesesky contributed equally to this study. † Jonathan M. Carlson, Harlan S. Robins, and John N. Aucott contributed equally to the oversight of this study. a Microsoft Research, Redmond, Washington, USA, and Cambridge, UK bAdaptive Biotechnologies, Seattle, Washington, USA c Stanford University School of Medicine, Stanford, California, USA d Lyme Disease Research Center, Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA e Lyme Disease Biobank, Portland, Oregon, USA

Expansion of Unique Hepatitis C Virus-Specific Public CD8 + T Cell Clonotypes during Acute Infection and Reinfection

Mazouz S, et al.
Journal of Immunology
August 2021
Authors and Affiliates
Sabrina Mazouz 1,2, Maude Boisvert 1, Mohamed S Abdel-Hakeem 1,2, Omar Khedr 1, Julie Bruneau 1,3, Naglaa H Shoukry 4,5; 1 Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada. 2 Département de Microbiologie, Infectiologie et Immunologie, Université de Montreal, Montreal, Quebec, Canada. 3 Département de Médecine Familiale et de Médecine d'Urgence, Université de Montréal, Montreal, Quebec, Canada; and. 4 Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada; naglaa.shoukry@umontreal.ca. 5 Département de Médecine, Université de Montréal, Montreal, Quebec, Canada.

Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial

Creelan BC, et al.
Nature Medicine
August 2021
Authors and Affiliates
Benjamin C Creelan #,1, Chao Wang #,2, Jamie K Teer 3, Eric M Toloza 2, Jiqiang Yao 3, Sungjune Kim 4, Ana M Landin 5, John E Mullinax 6, James J Saller 7, Andreas N Saltos 2, David R Noyes 4, Leighann B Montoya 8, Wesley Curry 8, Shari A Pilon-Thomas 4, Alberto A Chiappori 2, Tawee Tanvetyanon 2, Frederic J Kaye 9, Zachary J Thompson 2, Sean J Yoder 10, Bin Fang 10, John M Koomen 10, Amod A Sarnaik 2, Dung-Tsa Chen 3, Jose R Conejo-Garcia 2, Eric B Haura #,2, Scott J Antonia #,11; 1 Department of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. ben.creelan@moffitt.org. 2 Department of Thoracic Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. 3 Department of Bioinformatics and Biostatistics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. 4 Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. 5 Cell Therapy Facility, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. 6 Department of Sarcoma, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. 7 Department of Pathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. 8 Immune and Cellular Therapy Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. 9 Department of Medicine, University of Florida College of Medicine, Gainesville, FL, USA. 10 Chemical Biology & Molecular Medicine, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. 11 Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA. # Contributed equally.

Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T

Dorff T, et al.
Journal for ImmunoTherapy of Cancer
August 2021
Authors and Affiliates
Tanya Dorff 1, Yosuke Hirasawa 2, Jared Acoba 3, Ian Pagano 3, David Tamura 3, Sumanta Pal 1, Minlu Zhang 4, Rebecca Waitz 4, Abhilash Dhal 4, Winston Haynes 4, John Shon 4, Mark Scholz 5, Hideki Furuya 2, Owen T M Chan 3, Jeffrey Huang 3, Charles Rosser 6; 1 Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California, USA. 2 Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. 3 University of Hawaii Cancer Center, Honolulu, Hawaii, USA. 4 Serimmune, Goleta, California, USA. 5 Prostate Oncology Specialists, Marina del Rey, California, USA. 6 Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA charles.rosser@cshs.org.

GIANA allows computationally-efficient TCR clustering and multi-disease repertoire classification by isometric transformation

Zhang H, et al.
Nature Communications
August 2021
Authors and Affiliates
Hongyi Zhang 1, Xiaowei Zhan 2, Bo Li 3,4; 1 Lyda Hill Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX, USA. 2 Department of Population and Data Science, UT Southwestern Medical Center, Dallas, TX, USA. 3 Lyda Hill Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX, USA. bo.li@utsouthwestern.edu. 4 Department of Immunology, UT Southwestern Medical Center, Dallas, TX, USA. bo.li@utsouthwestern.edu.

Systemic inhibition of PTPN22 augments anticancer immunity

Ho WJ, et al.
JCI
August 2021
Authors and Affiliates
Won Jin Ho 1, Sarah Croessmann 2, Jianping Lin 3, Zaw H Phyo 1, Soren Charmsaz 1, Ludmila Danilova 1, Aditya A Mohan 1, Nicole E Gross 1, Fangluo Chen 1, Jiajun Dong 3, Devesh Aggarwal 3, Yunpeng Bai 3, Janey Wang 4, Jing He 4, James M Leatherman 1, Mark Yarchoan 1, Todd D Armstrong 1, Neeha Zaidi 1, Elana J Fertig 1, Joshua C Denny 4, Ben H Park 2, Zhong-Yin Zhang 3, Elizabeth M Jaffee 5; 1 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, United States of America. 2 Department of Medicine, Vanderbilt University Medical Center, Nashville, United States of America. 3 Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, United States of America. 4 Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, United States of America. 5 Sidney Kimmel Comprehensive Cancer Center, John Hopkins University, Baltimore, United States of America.

Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers

Caushi JX, et al.
Nature
July 2021
Authors and Affiliates
Justina X Caushi #,1,2,3, Jiajia Zhang #,1,2,3, Zhicheng Ji 4,5, Ajay Vaghasia 3, Boyang Zhang 4, Emily Han-Chung Hsiue 3,6,7, Brian J Mog 3,6,7, Wenpin Hou 4, Sune Justesen 8, Richard Blosser 1,3, Ada Tam 1,3, Valsamo Anagnostou 1,3, Tricia R Cottrell 1,2,3,9, Haidan Guo 1,2,3, Hok Yee Chan 1,2,3, Dipika Singh 1,2,3, Sampriti Thapa 1,2,3, Arbor G Dykema 1,2,3, Poromendro Burman 1,2,3, Begum Choudhury 1,2,3, Luis Aparicio 1,2,3, Laurene S Cheung 1,2,3, Mara Lanis 1,3, Zineb Belcaid 1,3, Margueritta El Asmar 1,3, Peter B Illei 3, Rulin Wang 3, Jennifer Meyers 3, Kornel Schuebel 3, Anuj Gupta 3, Alyza Skaist 3, Sarah Wheelan 3, Jarushka Naidoo 1,3,10, Kristen A Marrone 1,3, Malcolm Brock 3, Jinny Ha 3, Errol L Bush 3, Bernard J Park 11, Matthew Bott 11, David R Jones 11, Joshua E Reuss 3,12, Victor E Velculescu 1,3, Jamie E Chaft 11, Kenneth W Kinzler 3,6,7, Shibin Zhou 3,6,7, Bert Vogelstein 3,6,7, Janis M Taube 1,2,3, Matthew D Hellmann 11, Julie R Brahmer 1,3, Taha Merghoub 11,13,14, Patrick M Forde 1,3, Srinivasan Yegnasubramanian 15,16,17, Hongkai Ji 18, Drew M Pardoll 19,20,21, Kellie N Smith 22,23,24; 1 Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA. 2 The Mark Center for Advanced Genomics and Imaging at Johns Hopkins, Baltimore, MD, USA. 3 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA. 4 Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. 5 Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA. 6 Ludwig Center and Howard Hughes Medical Institute at Johns Hopkins, Baltimore, MD, USA. 7 Lustgarten Pancreatic Cancer Research Laboratory, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA. 8 Immunitrack, Copenhagen, Denmark. 9 Ontario Institute for Cancer Research, Queens University, Kingston, Ontario, Canada. 10 Beaumont Hospital Dublin, RCSI University of Medicine and Health Science, Dublin, Ireland. 11 Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York, NY, USA. 12 Georgetown Lombardi Comprehensive Cancer Center at Georgetown University, Washington, DC, USA. 13 The Swim Across America and Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center, New York, NY, USA. 14 Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 15 Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA. syegnasu@jhmi.edu. 16 The Mark Center for Advanced Genomics and Imaging at Johns Hopkins, Baltimore, MD, USA. syegnasu@jhmi.edu. 17 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA. syegnasu@jhmi.edu. 18 Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. hji@jhu.edu. 19 Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA. dpardol1@jhmi.edu. 20 The Mark Center for Advanced Genomics and Imaging at Johns Hopkins, Baltimore, MD, USA. dpardol1@jhmi.edu. 21 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA. dpardol1@jhmi.edu. 22 Bloomberg~Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD, USA. kellie@jhmi.edu. 23 The Mark Center for Advanced Genomics and Imaging at Johns Hopkins, Baltimore, MD, USA. kellie@jhmi.edu. 24 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA. kellie@jhmi.edu. # Contributed equally.

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

Andrews MC, et al.
Nature Medicine
July 2021
Authors and Affiliates
Miles C Andrews # 1 2 3, Connie P M Duong # 4 5 6, Vancheswaran Gopalakrishnan # 1, Valerio Iebba # 4 5, Wei-Shen Chen # 7 8, Lisa Derosa # 4 5 6, Md Abdul Wadud Khan 1, Alexandria P Cogdill 4 5 6 7, Michael G White 1, Matthew C Wong 7, Gladys Ferrere 4 5 6, Aurélie Fluckiger 4 5 6, Maria P Roberti 4 5 6, Paule Opolon 4, Maryam Tidjani Alou 4 5 6, Satoru Yonekura 4 5 6, Whijae Roh 7, Christine N Spencer 9, Irina Fernandez Curbelo 10, Luis Vence 10, Alexandre Reuben 11, Sarah Johnson 1, Reetakshi Arora 1, Golnaz Morad 1, Matthew Lastrapes 12, Erez N Baruch 7, Latasha Little 7, Curtis Gumbs 7, Zachary A Cooper 13, Peter A Prieto 14, Khalida Wani 15, Alexander J Lazar 7 15, Michael T Tetzlaff 15, Courtney W Hudgens 15, Margaret K Callahan 9 16, Matthew Adamow 16 17, Michael A Postow 16 17, Charlotte E Ariyan 18, Pierre-Olivier Gaudreau 1, Luigi Nezi 19, Didier Raoult 20, Catalin Mihalcioiu 21, Arielle Elkrief 22, Rossanna C Pezo 23, Lauren E Haydu 1, Julie M Simon 1, Hussein A Tawbi 24, Jennifer McQuade 24, Patrick Hwu 24, Wen-Jen Hwu 24, Rodabe N Amaria 24, Elizabeth M Burton 1, Scott E Woodman 7 24, Stephanie Watowich 10, Adi Diab 24, Sapna P Patel 24, Isabella C Glitza 24, Michael K Wong 24, Li Zhao 7, Jianhua Zhang 7, Nadim J Ajami 7, Joseph Petrosino 25, Robert R Jenq 7, Michael A Davies 24, Jeffrey E Gershenwald 1, P Andrew Futreal 7, Padmanee Sharma 10, James P Allison 10, Bertrand Routy 4 5 6, Laurence Zitvogel 26 27 28, Jennifer A Wargo 29 30; 1 Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2 Olivia Newton-John Cancer Research Institute and La Trobe University School of Cancer Medicine, Heidelberg, Victoria, Australia. 3 Deparment of Medicine, Monash University, Melbourne, Victoria, Australia. 4 Gustave Roussy Cancer Campus (GRCC), Villejuif, France. 5 Institut National de la Santé Et de la Recherche Medicale (INSERM) U1015, Equipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France. 6 Université Paris-Saclay, Faculté de Médecine Kremlin-Bicêtre, Le Kremlin-Bicêtre, France. 7 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 8 Department of Dermatology, University of South Florida Morsani College of Medicine, Tampa, FL, USA. 9 Department of Informatics, Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. 10 Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 11 Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 12 MD Anderson Cancer Center University of Texas Health Graduate School of Biomedical Sciences (GSBS), Houston, TX, USA. 13 AstraZeneca, Gaithersburg, MD, USA. 14 Department of Surgery, University of Rochester Medical Center, Rochester, NY, USA. 15 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 16 Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 17 Division of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 18 Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 19 Istituto Europeo di Oncologia, Milan, Italy. 20 Aix-Marseille Université, MEPHI, IRD, IHU Méditerranée Infection, Marseille, France. 21 Department of Medicine, Faculty of Medicine and Health Sciences, McGill University Health Centre, Montreal, Quebec, Canada. 22 Cedars Cancer Center, McGill University Health Centre, Montreal, Quebec, Canada. 23 Division of Medical Oncology, University of Toronto, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada. 24 Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 25 Department of Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA. 26 Gustave Roussy Cancer Campus (GRCC), Villejuif, France. laurence.zitvogel@gustaveroussy.fr. 27 Institut National de la Santé Et de la Recherche Medicale (INSERM) U1015, Equipe Labellisée-Ligue Nationale contre le Cancer, Villejuif, France. laurence.zitvogel@gustaveroussy.fr. 28 Université Paris-Saclay, Faculté de Médecine Kremlin-Bicêtre, Le Kremlin-Bicêtre, France. laurence.zitvogel@gustaveroussy.fr. 29 Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jwargo@mdanderson.org. 30 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jwargo@mdanderson.org. # Contributed equally.

Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma

Leko V, et al.
Journal for ImmunoTherapy of Cancer
July 2021
Authors and Affiliates
Vid Leko 1, Gal Cafri 2, Rami Yossef 3, Biman Paria 4, Victoria Hill 3, Devikala Gurusamy 3, Zhili Zheng 3, Jared J Gartner 3, Todd D Prickett 3, Stephanie L Goff 3, Paul Robbins 3, Yong-Chen Lu 3, Steven A Rosenberg 3; 1 Surgery Branch, National Cancer Institute, Bethesda, Maryland, USA vid.leko@nih.gov. 2 Sheba Medical Center, Ramat Gan, Israel. 3 Surgery Branch, National Cancer Institute, Bethesda, Maryland, USA. 4 Program Coordination and Referral Branch, National Cancer Institute, Bethesda, Maryland, USA.
Previous Next